Copley Pharmaceutical
This article was originally published in The Tan Sheet
Executive Summary
Deal with Ocular Research of Boston gives the generic drug manufacturer exclusive worldwide rights to manufacture and market a line of ophthalmic solutions developed by ORB. The line includes OTC lubricating and rewetting solutions for prescription contact lenses and artificial tear preparations. The solutions use "specialized lipids, including phospholipids, to reconstruct and thicken the tear film" to prevent drying of the eyes without blurring vision, Copley said. A premarket approval application was filed with FDA this year for the solutions, which have already been tested in 200 subjects and can be used with or without contact lenses.